RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024Although Trump did not disclose his intended healthcare policy changes during his 2024 campaign, Trump’s return to the White House may drive biopharmaceutical merger and acquisition (M&A) deal activity.
A change in USFTC leadership may encourage more M&A deals by large biopharmaceutical companies, as well as create a more favourable environment for smaller biotech companies to exit via acquisitions.
To bypass Trump’s proposed import tariffs of 60% on goods from China and 20% on imports from other ex-US countries, there may be an increase in M&A deals involving ex-US biopharmaceutical companies enabling the domestic manufacturing of drugs to sell in the US market.